

- oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. *Oncogene* 2000;19:5419–5427.
9. Morgan DO, Kaplan JM, Bishop JM, Varmus HE. Mitosis-specific phosphorylation of p60c-src by p34cdc2-associated protein kinase. *Cell* 1989;57:775–786.
 10. Yeatman TJ. A renaissance for SRC. *Nat Rev Cancer* 2004;4:470–480.
 11. Ellis LM, Staley CA, Liu W, et al. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. *J Biol Chem* 1998;273:1052–1057.
 12. Mukhopadhyay D, Tsiokas L, Zhou XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. *Nature* 1995;375:577–581.
 13. Laird AD, Li G, Moss KG, et al. Src family kinase activity is required for signal transducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. *Mol Cancer Ther* 2003;2:461–469.
 14. Gray MJ, Zhang J, Ellis LM, et al. HIF-1 α , STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. *Oncogene* 2006;24:3110–3120.
 15. Jiang BH, Agani F, Passaniti A, Semenza GL. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. *Cancer Res* 1997;57:5328–5335.
 16. Irby RB, Yeatman TJ. Role of src expression and activation in human cancer. *Oncogene* 2000;19:5636–5642.
 17. Masaki T, Igarashi K, Tokuda M, et al. pp60c-src activation in lung adenocarcinoma. *Eur J Cancer* 2003;39:1447–1455.
 18. Song L, Turkson J, Karras JG, Jove R, Haura EB. Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. *Oncogene* 2003;22:4150–4165.
 19. Wei L, Yang Y, Zhang X, Yu Q. Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. *Oncogene* 2004;23:9052–9061.
 20. Johnson FM, Saigal B, Talpaz M, Donato NJ. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. *Clin Cancer Res* 2006;11:6924–6932.
 21. Darnell JE. STATs and gene regulation. *Science* 1997;277:1630–1635.
 22. Haura EB, Turkson J, Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. *Nat Clin Pract Oncol* 2006;2:315–324.
 23. Yu H, Jove R. The STATs of cancer: new molecular targets come of age. *Nat Rev Cancer* 2004;4:97–105.
 24. Levy DE, Darnell JE. Stats: transcriptional control and biological impact. *Nat Rev Mol Cell Biol* 2002;3:651–662.
 25. Haura EB, Zheng Z, Song L, Cantor A, Bepko G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. *Clin Cancer Res* 2006;11:8288–8294.
 26. Niu G, Wright KL, Ma Y, et al. Role of Stat3 in regulating p53 expression and function. *Mol Cell Biol* 2006;25:7432–7440.
 27. Park S, Kim D, Kaneko S, et al. Molecular cloning and characterization of the human AKT1 promoter uncovers its up-regulation by the Src/Stat3 pathway. *J Biol Chem* 2006;280:38932–38941.
 28. Bowman T, Broome MA, Sinibaldi D, et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis. *Proc Natl Acad Sci USA* 2001;98:7319–7324.
 29. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. *Oncogene* 2002;21:2000–2008.
 30. Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. *Oncogene* 2006;24:5552–5560.
 31. Kortylewski M, Kujawski M, Wang T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. *Nat Med* 2006;11:1314–1321.
 32. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. *Nat Med* 2004;10:48–54.
 33. Dauer DJ, Ferraro B, Song L, et al. Stat3 regulates genes common to both wound healing and cancer. *Oncogene* 2005;29:3397–3408.
 34. Dechow TN, Pedranzini L, Leitch A, et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. *Proc Natl Acad Sci USA* 2004;101:10602–10607.
 35. Xie TX, Wei D, Liu M, et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. *Oncogene* 2004;23:3550–3560.
 36. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. *Clin Cancer Res* 2002;8:945–954.
 37. Turkson J. STAT proteins as novel targets for cancer drug discovery. *Expert Opin Ther Targets* 2004;8:409–422.

ERRATUM

Garfield DH, Cadranell JL, Wislez M, Franklin WA, Hirsch FR. The Bronchioloalveolar Carcinoma and Peripheral Adenocarcinoma Spectrum of Diseases. *J Thorac Oncol* 2006;1:344–359.

In the article that appeared on page 344 of the May 2006 issue, the author line and the Table of Contents should have listed the authors as follows: David H. Garfield, MD, Jacques L. Cadranell, MD, PhD, Marie Wislez, MD, PhD, Wilbur A. Franklin, MD, and Fred R. Hirsch, MD, PhD. This article was printed with a number of other errors. Please refer to the journal web site at www.jto.org for the final corrected version of this article. The citation for this article remains the same. The Editor regrets these errors.